Erasca says FDA grants fast-track status to ERAS-0015 for metastatic pancreatic cancer

Reuters2026/08/24 12:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Erasca secured FDA Fast Track status for ERAS-0015 to treat metastatic pancreatic adenocarcinoma, accelerating its regulatory path.
Preliminary Phase 1 findings were already presented in July 2026, showing early tumor shrinkage signals in previously treated pancreatic cancer.
Further Phase 1 monotherapy and combination updates are slated for H1 2027, with results to be presented in the future.
Development plans now center on a planned Phase 3 pancreatic study, alongside two potentially pivotal trials in lung cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608240800PRIMZONEFULLFEED9814688) on August 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Erasca says FDA grants fast-track status to ERAS-0015 for metastatic pancreatic cancer

You may also like

Crypto prices